ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

ACET Adicet Bio Inc

0.9261
0.0261 (2.90%)
Pre Market
Last Updated: 09:10:53
Delayed by 15 minutes
Share Name Share Symbol Market Type
Adicet Bio Inc NASDAQ:ACET NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.0261 2.90% 0.9261 0.889 0.90 2,426 09:10:53

Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

05/11/2024 12:00pm

Business Wire


Adicet Bio (NASDAQ:ACET)
Historical Stock Chart


From Aug 2024 to Feb 2025

Click Here for more Adicet Bio Charts.

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral presentation at the upcoming American College of Rheumatology (ACR) Convergence 2024 meeting, taking place November 14-19, 2024, in Washington, D.C.

Details of the oral presentation are as follows:

Title: ADI-001: An Allogeneic CD20-targeted γδ CAR T Cell Therapy with Potential for Improved Tissue Homing in Autoimmune Indications Session Name: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II Abstract Number: 1866169 Presenting Author: Monica Moreno, Ph.D. Date and Time: November 19, 2024; 12:00 p.m. – 12:15 p.m. ET

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

Adicet Bio., Inc. Investor and Media Contacts

Investors: Anne Bowdidge abowdidge@adicetbio.com

Janhavi Mohite Precision AQ 212-362-1200 janhavi.mohite@precisionaq.com

Media: Kerry Beth Daly kbdaly@adicetbio.com

1 Year Adicet Bio Chart

1 Year Adicet Bio Chart

1 Month Adicet Bio Chart

1 Month Adicet Bio Chart

Your Recent History

Delayed Upgrade Clock